HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.

International Conference On Orphan Drugs and Rare Diseases

August 21-23, 2023

August 17 -19, 2023 | London, UK

Orphan Drugs 2023

Speaker at Orphan Drugs and Rare Diseases 2023 - Harsha Rajasimha
Keynote Presentation
Harsha Rajasimha, Jeeva Informatics Solutions Inc, United States

Will be Updated Soon...

Speaker at Orphan Drugs and Rare Diseases 2023 - Candida Fratazzi
Keynote Presentation
Candida Fratazzi, BBCR Consulting - Massachusetts, United States

Will be Updated Soon...

Speaker at Orphan Drugs and Rare Diseases 2023 -  Daniel Scherman
Keynote Presentation
Daniel Scherman, Fondation Maladies Rares, France

The French rare disease research and clinical field has been a pioneer by structuring itself through different action plans. Competence centres and Reference centres are organized within  Rare Disease Health Networks (Filières de Santé Maladies Rares), which ha [....] » Read More

Speaker at Orphan Drugs and Rare Diseases 2023 - Magali Taiel
Oral Presentation
Magali Taiel, GenSight Biologics, France

Leber hereditary optic neuropathy (LHON) is a rare, maternally inherited mitochondrial genetic disease with a continued high unmet medical need. Three primary point mutations in the mtDNA are responsible for LHON in approximately 90% of subjects: G3460A, G11778A and T14484C, loca [....] » Read More

Speaker at Orphan Drugs and Rare Diseases 2023 - Yehuda Shoenfeld
Oral Presentation
Yehuda Shoenfeld, Ariel University, Israel

Covid-19 virus is an autoimmune virus and  it is more notorious than EBV. It induces autoimmune diseases by hyper-stimulation  of the immune system combined in molecular mimicry. Post COVID-19 Syndrome (PCS) is a complex of various symptoms developing a month or more [....] » Read More

Speaker at Orphan Drugs and Rare Diseases 2023 - Wolfgang K.H. Oelkers
Oral Presentation
Wolfgang K.H. Oelkers, Freie Universität Berlin, Germany

Plenadren ( 20 and 5 mg tablets of modified release hydrocortisone (HC)), was developed for substituting patients with primary (prim) and secondary (sec) Adrenal Insufficiency (AI) with a single morning glucocorticoid (GC) dose. The orphan status was based on a single publication [....] » Read More

Speaker at Orphan Drugs and Rare Diseases 2023 - Craig Martin
Oral Presentation
Craig Martin, Global Genes, United States

Short Description of what will be discussed during the presentation (about 250 - 500 words)   Patient data is perhaps the most valuable asset rare disease communities can leverage to generate research interest and spur drug development. Initiatives to drive the collect [....] » Read More

Speaker at Orphan Drugs and Rare Diseases 2023 -  Victor Shengkan jin
Keynote Presentation
Victor Shengkan jin, Rutgers University, United States

Will be Updated Soon...

Speaker at Orphan Drugs and Rare Diseases 2023 - Fereshteh Sedaghat
Oral Presentation
Fereshteh Sedaghat, Aristotle University, Greece

The proteoglycan named heparan sulfate (HS) is found in the extracellular matrix and also on cell surface and may represent one of the most biologically important glycoconjugates, playing essential role in a variety of different events at molecular level. Heparanase is an endo-gl [....] » Read More

Speaker at Orphan Drugs and Rare Diseases 2023 -  Jiao Fuyong
Keynote Presentation
Jiao Fuyong, Children’s Hospital of Shaanxi Provincial People’s Hospital, China

Kawasaki disease,It is a systemic vasioinflammatory disease in children of Asian descent,Coronary artery injury is its major complication,The disease has now become a major cause of acquired heart disease in children.The etiology of Kawasaki disease is not fully clear, and its pa [....] » Read More

Watsapp